Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis

Phase 3

Completed

• Conditions: Tinea Pedis; Athlete's Foot
• Interventions: Drug: NAFT-500; Drug: Placebo 2-weeks; Drug: Naftin 1%; Drug: Placebo 4-weeks

• Registration Number: NCT00750139
• Lead Sponsor: Merz North America, Inc.

Brief Summary

A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo, when used in subjects with tinea pedis (athlete's foot).

Detailed Description

To evaluate the efficacy and safety of NAFT-500 compared to placebo in the treatment of subjects with potassium hydroxide (KOH) and culture positive symptomatic tinea pedis.

Study Timeline

• Study Start: 2008-08
• Study First Submitted: 2008-09-08
• Study First Submitted QC: 2008-09-09
• Study First Posted: 2008-09-10
• Primary Completion: 2009-08
• Study Completion: 2009-12
• Disposition First Submitted: 2011-06-14
• Disposition First Submitted QC: 2011-07-11
• Disposition First Posted: 2011-07-14
• Results First Submitted: 2012-02-13
• Results First Submitted QC: 2012-12-18
• Results First Posted: 2013-01-29
• Status Verified: 2013-04
• Last Update Submitted: 2013-04-19
• Last Update Posted: 2013-04-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 707

Inclusion Criteria

1. Review and sign a statement of Informed Consent and HIPAA authorization.
2. For minors (less than 18 years), the parent/legal guardian must complete the informed consent process AND the subject must complete the assent process and sign the appropriate form (if age appropriate).
3. Males or non-pregnant females ≥12 years of age, of any race or sex. Females of childbearing potential must have a negative urine pregnancy test.
4. Presence of tinea pedis on one or both feet characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling, and mild pruritus)based on signs and symptoms.
5. KOH positive and culture positive baseline skin scrapings obtained from the site most severely affected or a representative site of the overall severity.
6. Subjects must be in good health and free from any clinically significant disease that might interfere with the study evaluations.
7. Subject must be able to understand the requirements of the study and willing to comply with the study requirements.

Exclusion Criteria

1. A life-threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months.

2. Subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results.

3. Subjects with a known hypersensitivity to study medications or their components.

4. Subjects who have a recent history or who are currently known to abuse alcohol or drugs.

5. Uncontrolled diabetes mellitus.

6. Hemodialysis or chronic ambulatory peritoneal dialysis therapy.

7. Current diagnosis of immunocompromising conditions.

8. Foot psoriasis, corns and/or callus involving any web spaces, atopic or contact dermatitis.

9. Severe dermatophytoses, onychomycosis (on the evaluated foot), mucocutaneous candidiasis, or bacterial skin infection.

10. Extremely severe tinea pedis (incapacitating).

11. Female subject who is pregnant or lactating, who is not using or does not agree to use an acceptable form of contraception during the study, or who intends to become pregnant during the study (females who are surgically sterilized or post menopausal for at least 2 years are not considered to be of childbearing potential).For the purposes of this study, acceptable forms of birth control include: oral contraceptives, contraceptive patches/implants, double barrier methods (e.g., use of condom and spermicide), IUD, and abstinence with second acceptable method should subject become sexually active.

12. Subjects using the following medications:

    • Topical anti-fungal therapy, foot/shoe powders, or topical corticosteroids applied to the feet within 14 days prior to randomization. Topical terbinafine, butenafine,and naftifine within 30 days prior to randomization
    • Oral anti-fungal therapies 3 months (8 months for oral terbinafine) prior to randomization
    • Systemic antibiotic or corticosteroid treatment within 30 days of randomization
    • Any other significant treatments, except hormonal contraception and multivitamin, at the discretion of the investigator that would interfere with study treatment.
    • Investigational drug within 30 days of randomization

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	NAFT-500	Naftin 2% cream applied daily for 2 weeks
2	Placebo 2-weeks	Placebo cream applied daily for two weeks
3	Naftin 1%	Active comparator applied daily for 4 weeks
4	Placebo 4-weeks	placebo cream applied daily for 4 weeks

Primary Outcome Measures

Name	Time	Method
Percentage of Subjects With Complete Cure at Week 6.	Week 6	The first primary efficacy variable was the percentage of subjects in the NAFT-500 Cream, 2% or 2-week placebo groups with complete cure at Week 6.; The second primary efficacy variable was the percentage of subjects in the Naftin 1% Cream or 4-week placebo groups with complete cure at Week 6.; Complete cure was defined as negative mycology results from the central laboratory (dermatophyte culture and KOH) and absence of erythema, scaling, and pruritus that were evaluated using a 4 point severity scale.

Secondary Outcome Measures

Name	Time	Method
Percentage of Subjects With Mycological Cure and Percentage of Subjects With Treatment Effectiveness at Week 6	Week 6	Mycological Cure was defined as negative KOH result and negative dermatophyte culture at Week 6. Treatment Effectiveness was defined as negative KOH, negative culture, and Scaling, Erythema, and Pruritus grades of 0 or 1 at Week 6.

Trial Locations

Locations (15)

Research Across America; 🇺🇸 Plano, Texas, United States

Silverton Skin Institute; 🇺🇸 Grand Blanc, Michigan, United States

Glazer Dermatology; 🇺🇸 Buffalo Grove, Illinois, United States

Haber Dermatology; 🇺🇸 Euclid, Ohio, United States

Dr. Felix Sigal; 🇺🇸 Los Angeles, California, United States

Oregon Dermatology and Research Center; 🇺🇸 Portland, Oregon, United States

FXM Research; 🇺🇸 Miramar, Florida, United States

Zoe Draelos, MD; 🇺🇸 High Point, North Carolina, United States

University of California San Francisco, Dept of Dermatology; 🇺🇸 San Francisco, California, United States

Temple University School of Podiatric Medicine; 🇺🇸 Philadelphia, Pennsylvania, United States

Tulane University Health Services; 🇺🇸 New Orleans, Louisiana, United States

Paddington Testing Company; 🇺🇸 Philadelphia, Pennsylvania, United States

Coastal Carolina Research Center; 🇺🇸 Mt. Pleasant, South Carolina, United States

J & S Studies; 🇺🇸 College Station, Texas, United States

Radiant Research; 🇺🇸 Birmingham, Alabama, United States